Ingredientsβ-Cryptoxanthin (beta-cryptoxanthin; systematic name: (3R)-β,β-caroten-3-ol; sometimes also called β,β-caroten-3-ol) is the predominant and most biologically significant member of the cryptoxanthin group of carotenoids. Two other structural isomers exist—α-cryptoxanthin (β,ε-caroten-3′-ol) and zeinoxanthin (β,ε-caroten-3-ol)—but β-cryptoxanthin is by far the most abundant and well-studied in human nutrition. When the unqualified term "cryptoxanthin" appears in the scientific or nutritional literature, it typically refers to the β form.
β-Cryptoxanthin is a provitamin A carotenoid classified as a xanthophyll, featuring an oxygenated structure with a single hydroxyl group that renders it more polar and hydrophilic than β-carotene, and possessing the molecular formula C₄₀H₅₆O. In terms of structure, β-cryptoxanthin is closely related to β-carotene, with only the addition of a hydroxyl group. It consists of 11 conjugated double bonds and constitutes a bicyclic compound in which the carbon at position 3 of one of the rings is substituted with a hydroxyl group.
In pure form, β-cryptoxanthin is a red crystalline solid with a metallic luster. It is freely soluble in chloroform, benzene, pyridine, and carbon disulfide, and is insoluble in water like most β-carotenoids. Carotenoids absorb light in the 400–500 nm region of the visible spectrum and have a common chemical feature: a poly-isoprenoid structure, a long conjugated chain of double bonds in the central portion of the molecule, and near symmetry around the central double bond.
Carotenoids are classified into hydrocarbon carotenoids—with lycopene and beta-carotene being the important members—and oxycarotenoids (xanthophylls), to which belongs mono-hydroxylated β-cryptoxanthin, while lutein, zeaxanthin, and astaxanthin are dihydroxylated. The biosynthetic pathway of enzymatic hydroxylation of symmetrical β-carotene (β,β-carotene) leads to the formation of β-cryptoxanthin (β,β-caroten-3-ol).
β-Cryptoxanthin occurs naturally as both free and esterified forms in fruits and vegetables, and the distribution of free β-cryptoxanthin and β-cryptoxanthin esters is dependent upon plant type and environmental conditions. Among the 20 carotenoids detected in mammalian plasma and tissues, β-cryptoxanthin is one of the major carotenoids detected along with lutein, zeaxanthin, β-carotene, and lycopene, together accounting for nearly 90% of the carotenoids.
β-Cryptoxanthin is one of the six main carotenoids found in human plasma and is beneficial to human health. In nature, its accumulation is not a common event; it is massively accumulated in only a few fruits such as papaya, persimmon, citrus, and guava, with citrus fruits being major sources for the human diet.
Notable concentrations occur in tangerines (407–775 µg/100 g), papaya (589 µg/100 g), butternut squash (3,471 µg/100 g), sweet red peppers, and orange juice (169 µg/100 g). The highest concentrations occur in orange-fleshed fruits such as persimmons (up to 1.45 mg/100 g fresh weight), papaya (up to 0.59 mg/100 g), and tangerines (up to 0.49 mg/100 g), as well as in Physalis fruits. Other notable plant sources include red bell peppers (0.49–0.73 mg/100 g) and winter squashes like butternut squash (up to 3.47 mg/100 g).
An edible portion of Satsuma mandarin contains about 1.8 mg/100 g of β-cryptoxanthin, while Valencia orange contains about 0.2 mg/100 g and grapefruit contains almost none. In animal-derived foods, β-cryptoxanthin occurs only in trace amounts, resulting from the animals' dietary intake of carotenoid-rich plants. Mammalian species do not synthesize carotenoids and therefore must obtain them from dietary sources such as fruits and vegetables and/or dietary supplements.
The use of β-cryptoxanthin as a nutritional supplement, food additive, and food colorant has stimulated a variety of approaches to identify and quantify free β-cryptoxanthin and β-cryptoxanthin esters, with advances in high-performance liquid chromatography (HPLC) coupled with UV and mass spectrometry (MS) playing a key role.
In view of increasing research interest, there have been several approaches to commercially produce this carotenoid: (1) from natural sources as extracts rich in β-cryptoxanthin, (2) by biotechnology routes, and (3) by total- and semi-synthesis. One important approach involves preparation of the β-cryptoxanthin concentrate from plant oleoresin, especially from Capsicum oleoresin, by admixing the oleoresin with alcohol solvents, saponifying the xanthophyll esters, washing and purifying by eluting the crude xanthophyll on a silica gel column, and further purifying to obtain high-purity trans-β-cryptoxanthin enriched concentrate crystals.
Enzyme-processed Satsuma mandarin (EPSM) is one commercial form, manufactured as an orange powder made from Satsuma mandarin pulp after juicing, containing a minimum of 0.2% (w/w) β-cryptoxanthin. As a supplement, β-cryptoxanthin is commonly presented in softgel capsules or tablets containing concentrated citrus extracts or purified isolates in an oily excipient to enhance fat-soluble absorption.
β-Cryptoxanthin as an isolated phytochemical has no codified history of traditional or ethnobotanical use, because it was not identified as a distinct compound until the modern era of analytical chemistry. Its nutritional history is inseparable from the traditional and widespread consumption of the foods that contain it.
β-Cryptoxanthin is abundant in vegetables and fruits such as Satsuma mandarin, papaya, and persimmon, which have a long dietary history. Satsuma mandarin, also known as table orange or Satsuma in western countries, is one of the most popular citrus fruits in Japan; it is sweet, tasty, and rich in vitamin C, and it is one of the most β-cryptoxanthin-rich fruits in the world.
The major food sources of cryptoxanthin in most diets are citrus fruits, including orange and fruit juices. Cryptoxanthin consumption varies widely by country, with unusually high consumption in Spain and Japan, because mandarin oranges, which contain high amounts of β-cryptoxanthin, are consumed daily in Japan. Because β-cryptoxanthin is rarely found in most fruits or vegetables, serum β-cryptoxanthin concentration is almost parallel to Satsuma mandarin consumption in the Japanese population and is higher than in western populations.
Epidemiological research into β-cryptoxanthin has been driven in part by observations of unusually high serum β-cryptoxanthin levels in Japanese cohorts from citrus-growing regions—most notably from the Mikkabi cohort study in Shizuoka Prefecture—where residents consume large quantities of Satsuma mandarins. Numerous recent epidemiological studies have demonstrated that a high dietary consumption of fruits and vegetables rich in carotenoids, or high serum carotenoid concentrations, results in lower risks of certain cancers, diabetes, and cardiovascular disease, suggesting that antioxidant carotenoids may have a protective effect against several lifestyle-related diseases.
In the body, β-cryptoxanthin is absorbed in the small intestine via scavenger receptor class B type I (SR-BI) and passive diffusion, with bioavailability up to 725% higher than that of β-carotene from similar foods due to its enhanced incorporation into mixed micelles. It serves as a precursor to retinol (vitamin A) through enzymatic cleavage by β-carotene 15,15′-monooxygenase 1 (BCMO1), with a conversion efficiency requiring 24 µg of β-cryptoxanthin to yield 1 µg retinol activity equivalents (RAE).
Provitamin A is known to serve as a supply source of retinoids through metabolic conversion by the regulated activity of BCMO1 to the retina only when retinoids are deficient. Some research indicates that the bioavailability of β-cryptoxanthin in typical diets is greater than that of other major carotenoids, suggesting that β-cryptoxanthin-rich foods are probably good sources of carotenoids.
β-Cryptoxanthin, a carotenoid found in fruits and vegetables such as tangerines, red peppers, and pumpkin, has several functions important for human health. Most evidence from observational, in vitro, animal model, and human studies suggests that it has relatively high bioavailability from common food sources. β-Cryptoxanthin is an antioxidant in vitro and appears to be associated with decreased risk of some cancers and degenerative diseases.
From mechanistic studies using NAFLD-model mice, β-cryptoxanthin has been shown to contribute to improvement of NAFLD through a multifaceted approach, including improved insulin resistance, suppression of oxidative stress and inflammation, a reduction of macrophages and a shift of their subsets, and control of lipid metabolism by peroxisome proliferator-activated receptor (PPAR) family activation. β-Cryptoxanthin has the potential to prevent lifestyle-related diseases from different angles, not only as an antioxidant but also as a retinoid precursor.
DNA microarray analysis strongly indicates that oral administration of β-cryptoxanthin represses the inflammatory cytokine secretion and improves lipid metabolism and energy consumption, and these effects are partly mediated by PPAR-α, not only in lipid metabolism and adipocyte differentiation control but possibly through internal circadian clock modulation.
β-Cryptoxanthin has stimulatory effects on osteoblastic bone formation and inhibitory effects on osteoclastic bone resorption in vitro, thereby increasing bone mass. β-Cryptoxanthin has an effect on the gene expression of various proteins related to osteoblastic bone formation and mineralization in vitro. It also has inhibitory effects on enzyme activity related to osteoclastic bone resorption, and the carotenoid induces apoptosis of mature osteoclastic cells in vitro.
In vivo animal studies show that β-cryptoxanthin impeded osteoclast activation, urinary calcium excretion, and bone resorption, contributing to increased bone calcium, bone mineral density (BMD), bone formation, and bone mechanical strength and protecting against fragility.
The bone-related effects of β-cryptoxanthin represent one of the most extensively studied areas. Evidence spans in vitro, animal, and human epidemiological studies.
Oral administration of β-cryptoxanthin has been shown to have anabolic effects on bone components in young and aged rats, and the administration has preventive effects on bone loss in streptozotocin-diabetic rats and ovariectomized rats in vivo. Moreover, the intake of β-cryptoxanthin-reinforced juice for longer periods has been shown to have both stimulatory effects on bone formation and inhibitory effects on bone resorption in healthy human subjects and in postmenopausal women.
A systematic review and meta-analysis extracted data from 15 eligible studies. Among the 15 studies, seven including 100,496 individuals provided information for the meta-analysis. A random effects model was applied to integrate the odds ratio (OR) to compare the risk of osteoporosis between groups with high and low intake of β-cryptoxanthin. A high intake of β-cryptoxanthin was significantly correlated with a reduced risk of osteoporosis (OR = 0.79, 95% CI 0.70–0.90, p = 0.0002).
The primary result of this meta-analysis was that a high amount of dietary β-cryptoxanthin was significantly correlated with a low risk of osteoporosis. In subgroup analyses, females benefited more than males when they consumed a high amount of β-cryptoxanthin.
A notable limitation of this evidence base, as identified within the meta-analysis itself, is that methodological description of selective analysis on blood β-cryptoxanthin as compared with its structural isomer, α-cryptoxanthin, was insufficient in most of the studies, and a potential contribution of α-cryptoxanthin on the reduction of osteoporosis risk cannot be ruled out from the meta-analysis result; further interventional studies on each component are needed. The bulk of the human evidence remains observational; large randomized controlled trials (RCTs) specifically on supplemental β-cryptoxanthin and fracture endpoints are lacking.
Multiple epidemiological and some experimental studies have investigated the relationship between β-cryptoxanthin and lung cancer risk.
Between April 1993 and December 1998, 63,257 Chinese men and women aged 45–74 years in Singapore participated in a prospective study of diet and cancer, with in-person interviews and a structured questionnaire assessing dietary habits and other lifestyle factors. The study demonstrated a statistically significant, inverse association between dietary β-cryptoxanthin and lung cancer risk that is independent of cigarette smoking at the level of detail measured.
After additional adjustments for residual confounding by smoking using statistical models, approximately 15–40% reduction in risk of lung cancer was seen for subjects in the highest versus lowest tenth percentile of dietary β-cryptoxanthin, lending additional credence to the hypothesis that dietary β-cryptoxanthin is a chemopreventive agent for lung cancer in humans.
A pooled analysis of seven cohort studies in North America and Europe calculated study-specific multivariate relative risks across up to 7–16 years of follow-up, during which 3,155 incident lung cancer cases were diagnosed among 399,765 participants. This is consistent with epidemiological studies showing an inverse association between intakes or blood levels of β-cryptoxanthin and the risk of developing lung cancer, with high intake particularly associated with a decreased risk among current smokers.
Experimental evidence from a ferret model provided the first in vivo intervention evidence that β-cryptoxanthin at both dietary and supplemental doses significantly decreased cigarette smoke-induced lung precancerous lesions. At the mechanistic level, data from NHANES III showed that high serum levels of β-cryptoxanthin are associated with lower risk, and in a mouse study, supplementation of β-cryptoxanthin two weeks prior to carcinogen injection was effective in reducing lung tumor multiplicity by 52–63%, indicating that the chemopreventive activity was able to suppress tumor promotion rather than inhibit the initiation of tumorigenesis.
Evidence strength: Epidemiological evidence for an association between β-cryptoxanthin and reduced lung cancer risk is consistent across multiple cohort studies, but is observational by design and thus susceptible to residual confounding by smoking and other dietary variables. No interventional RCTs specifically testing β-cryptoxanthin supplementation and lung cancer incidence have been reported. Animal and in vitro data are supportive but not conclusive for humans.
In the Iowa Women's Health Study, a prospective study of 29,368 women (aged 55–69 years at baseline) carried out from 1986 through 1997, only β-cryptoxanthin and zinc intake had statistically significant inverse association with risk of rheumatoid arthritis.
In a separate population-based prospective study, the mean daily intakes of β-cryptoxanthin were 40% lower in cases than in controls. Subjects in the top one-third of intake of β-cryptoxanthin were at a lower risk of developing inflammatory polyarthritis than subjects in the lowest one-third (odds ratio: 0.51; 95% CI 0.25–1.02), and the association with β-cryptoxanthin was significant after adjustments for total energy, protein intake, and cigarette smoking.
These data are consistent with previous evidence showing that a modest increase in β-cryptoxanthin intake, equivalent to one glass of freshly squeezed orange juice per day, is associated with a reduced risk of developing inflammatory disorders such as rheumatoid arthritis.
Evidence strength: Evidence for joint/inflammatory benefits is primarily from observational epidemiological studies. No RCTs have investigated β-cryptoxanthin supplementation for arthritis endpoints in humans.
β-Cryptoxanthin administration repressed the elevation of body weight, serum lipid levels, and adipose tissue weight in obese model mice, indicating that it could prevent metabolic syndrome in both mice and humans.
A human clinical trial on mildly obese men revealed that oral intake of Satsuma mandarin-derived β-cryptoxanthin decreased visceral fat, body weight, and waist circumference. Further investigation revealed that β-cryptoxanthin specifically affected the development, enlargement, and lipid accumulation of adipocytes.
A cross-sectional study investigating the relation between 98 nutritional factors and BMI in Japanese individuals showed that only intake of β-cryptoxanthin was inversely correlated with BMI.
A Caenorhabditis elegans model was used to analyze in vivo the activity of β-cryptoxanthin on fat reduction and protection against oxidative stress. Dose-response assays provided evidence of efficacy at very low dose (0.025 µg/mL), and a comparative analysis with other carotenoids showed a stronger effect of β-cryptoxanthin than lycopene and β-carotene. Transcriptomic analysis revealed upregulation of energy metabolism, response to stress, and protein homeostasis as the main metabolic targets, collectively providing new in vivo evidence of potential therapeutic use in the prevention of diseases related to metabolic syndrome and aging.
Evidence strength: Preliminary to moderate. Human clinical data from small trials and cross-sectional studies are suggestive of a benefit on body composition and visceral fat, but large, well-controlled RCTs are lacking. Animal and in vitro evidence is supportive.
While the risk of developing type 2 diabetes was analyzed using fasting blood glucose ≥7 mmol/L as a diagnostic criterion in a Japanese cohort, groups with higher β-cryptoxanthin concentrations were found to have a significantly lower risk than the lower concentration group. An epidemiological study in Finland also reported that β-cryptoxanthin intake reduces the risk of developing type 2 diabetes, which is consistent with results of the Mikkabi Cohort Study.
Regarding the risk of developing dyslipidemia, one of the diagnostic criteria for metabolic syndrome, a significant inverse correlation was shown with the concentrations of α-carotene, β-carotene, and β-cryptoxanthin (provitamin A carotenoids).
From mechanistic studies using NAFLD-model mice, β-cryptoxanthin has been shown to contribute to the improvement of NAFLD through a multifaceted approach, including improved insulin resistance, suppression of oxidative stress and inflammation, a reduction of macrophages and a shift of their subsets, and control of lipid metabolism by PPAR family activation.
Evidence strength: Human data are observational (cohort and cross-sectional studies), with mechanistic support from animal models. No RCTs adequately powered to detect effects on diabetes incidence have been conducted.
β-Cryptoxanthin has recently gained attention for its risk-reducing effects on lifestyle-related diseases, especially on NAFLD, from epidemiological, interventional, and mechanistic studies.
A follow-up study on the risk of developing non-alcoholic liver dysfunction using serum alanine aminotransferase (ALT) concentration as a marker of liver damage revealed that the risk of developing NAFLD was significantly reduced in the high serum provitamin A concentration group.
One human study reported that plasma levels of carotenoids—including β-cryptoxanthin—were significantly decreased in patients with non-alcoholic steatohepatitis (NASH) compared to control subjects.
Evidence strength: Epidemiological associations and mechanistic animal data are available. Human interventional data are limited. Causal direction is not fully established.
Dietary antioxidants such as carotenoids may play a role in preventing cardiovascular disease mortality, but evidence remains mixed. A study analyzed data from 6,601 participants aged 40 years and above with metabolic syndrome from NHANES III and NHANES 2001–2006, in which serum concentrations of α-carotene, β-carotene, lycopene, β-cryptoxanthin, and combined lutein/zeaxanthin were quantified with participants followed for a median of 16.8 years.
In one cross-sectional analysis of cardiovascular-kidney-metabolic syndrome risk, β-cryptoxanthin did not show a statistically significant association, in contrast to several other carotenoids. Overall, evidence linking β-cryptoxanthin specifically to cardiovascular endpoints is less consistent than for other carotenoids such as lycopene.
β-Cryptoxanthin is a dietary carotenoid for which there have been few studies on safety and pharmacokinetics following daily oral supplementation. In one key double-blind, randomized, placebo-controlled clinical trial, 90 healthy Asian women between 21 and 35 years were randomized into three groups receiving 3 mg/day or 6 mg/day oral β-cryptoxanthin, or placebo. Plasma carotenoid levels were measured at 2, 4, and 8 weeks of supplementation.
Plasma β-cryptoxanthin concentration was significantly higher in the 6 mg/day group (9.0 ± 4.1 µmol/L) compared to the 3 mg/day group (6.0 ± 2.6 µmol/L) and placebo (0.4 ± 0.1 µmol/L) after 8 weeks. Plasma all-trans retinol, α-cryptoxanthin, α-carotene, β-carotene, lycopene, lutein, and zeaxanthin levels were not significantly changed, and no effects were found on blood retinol-dependent gene expression, mood, physical activity and sleep, metabolic parameters, or fecal microbial composition.
The dosage for the pharmacokinetic study (3 and 6 mg/day) was chosen to be comparable with previous supplementation of partially purified and concentrated Satsuma mandarin extracts (3.3–6.0 mg/day). The duration of 8 weeks was chosen to be comparable with previous β-cryptoxanthin supplementation studies lasting 3 to 12 weeks.
The available human intervention trials examining the effect of β-cryptoxanthin supplementation on a variety of outcomes have reported oral doses ranging from 0.75 mg/day upward. Because carotenoids do not meet the criteria for being considered vitamins, there is no daily recommended intake for them.
The first RCT to examine the effects of a pure encapsulated form of β-cryptoxanthin in healthy women found that multiple doses of β-cryptoxanthin of up to 6 mg/day for 8 weeks were well tolerated. No serious adverse events were observed.
Oral β-cryptoxanthin supplementation over 8 weeks led to high plasma concentrations of β-cryptoxanthin, with no impact on other carotenoids, and was well tolerated in healthy women.
The formal safety study involved only healthy Asian women; it would be of interest to determine whether men and other ethnic groups respond in the same way to β-cryptoxanthin supplementation. The study serves well for future clinical trials where the effects of β-cryptoxanthin supplementation on metabolic or mental health in women are investigated.
Because β-cryptoxanthin is converted to retinol (vitamin A) in a regulated, demand-sensitive manner by BCMO1, concerns about preformed vitamin A toxicity at food-level intakes are generally not considered applicable. However, vitamin A (retinol), which is formed from carotenoids in animals and humans, has been shown to have a role in the regulation of bone cells and may have an anabolic effect on bone. However, vitamin A is also known to have a detrimental effect on bone at high doses; in laboratory animals, high levels of vitamin A lead to accelerated bone resorption, bone fractures, and osteoporotic bone lesions. Whether highly supraphysiological supplemental doses of provitamin A carotenoids could approach this threshold in humans has not been established in clinical studies to date.
In the 8-week pharmacokinetic RCT, plasma all-trans retinol, α-cryptoxanthin, α-carotene, β-carotene, lycopene, lutein, and zeaxanthin levels were not significantly changed by supplementation at 3 or 6 mg/day, suggesting that at studied doses, β-cryptoxanthin supplementation did not competitively displace other carotenoids from plasma.
β-Cryptoxanthin is abundantly present in the Satsuma mandarin (Citrus unshiu Marc.), one of the most popular fruits in Japan. Human trials showed that its serum transfer efficiency was statistically higher in an emulsified formulation than in fresh Satsuma mandarin, indicating that the food matrix and processing state substantially influence bioavailability.
β-Cryptoxanthin is absorbed in the small intestine, enters the circulation, and accumulates in the body in white adipose tissue, the liver, and other organs. As a fat-soluble compound, co-ingestion with dietary fat is expected to enhance its absorption, consistent with general xanthophyll pharmacokinetics.
Aside from its provitamin A activity, β-cryptoxanthin appears to have a range of beneficial functions in the body; however, investigations on this carotenoid have not gone beyond epidemiological, cell culture, and animal studies for many of the claimed mechanisms and outcomes. The absence of large, preregistered RCTs with clinical endpoints means that causality has not been established for most health claims. β-Cryptoxanthin has the potential to prevent lifestyle-related diseases from different angles, not only as an antioxidant but also as a retinoid precursor, but the translation from observational data and mechanistic studies to confirmed clinical benefits remains an active area requiring further investigation.
Health conditions that Cryptoxanthin may help support.
BCX is a potent chain-breaking antioxidant that scavenges singlet oxygen and lipid peroxyl radicals. It uniquely also stimulates DNA base-excision repair in human cells, doubling the rate of removal of oxidized purines. Serum BCX is inversely correlated with oxidative DNA damage markers and lipid peroxidation indices in humans.
β-Cryptoxanthin suppresses aggrecanase-mediated articular cartilage degradation in arthritic animal models and inhibits IL-1β-driven inflammatory cytokine expression in primary chondrocytes. Epidemiological studies associate higher BCX intake with reduced risk of inflammatory polyarthritis.
Multiple human epidemiological studies and a meta-analysis of 15 studies (100,496 individuals) associate higher β-cryptoxanthin intake with significantly reduced osteoporosis risk (OR=0.79, 95% CI 0.70–0.90). In vitro work shows β-cryptoxanthin directly stimulates osteoblastic bone formation and inhibits osteoclastic bone resorption. Animal studies confirm prevention of ovariectomy-induced bone mineral density loss at doses of 50–100 µg/kg.
β-Cryptoxanthin demonstrates anti-inflammatory activity by downregulating NF-κB, TNF-α, IL-6, and IL-8 signaling pathways. Epidemiological studies associate higher BCX intake with reduced inflammatory disease risk. Animal studies show BCX reduces macrophage M1 polarization and attenuates high-fat-diet-induced inflammatory markers.
β-Cryptoxanthin is a provitamin A carotenoid with antioxidant and anti-inflammatory activity in retinal tissue. Animal studies demonstrate it protects against light-induced photoreceptor damage by reducing oxidative stress and mitochondrial DNA damage. As a provitamin A source, it contributes to retinol supply for visual cycle function.
BCX reduces oxidative DNA damage, stimulates DNA base-excision repair in human cells, and cross-sectional NHANES analyses link higher BCX intake to lower biological aging indices. Animal data show it prevents cognitive dysfunction and oxidative damage in aging models.
BCX has been shown to prevent adiposity accumulation in animal models, modulating lipid metabolism via PPAR-α activation and reducing adipocyte hypertrophy. Serum BCX is inversely associated with obesity markers in human observational data, and it reduces metabolic markers in high-fat-diet rodent models.
Observational data link higher BCX intake to reduced cardiovascular disease risk, oxidized LDL, and arterial inflammation. BCX suppresses NF-κB-driven endothelial inflammation and improves cardiometabolic markers in animal models. Serum carotenoid studies in metabolic syndrome populations support an inverse relationship with cardiovascular mortality.
Serum BCX is inversely associated with insulin resistance indices in non-diabetic humans. BCX enhances p-IRS-1 signaling and PPAR-α expression in insulin-resistant rodents, and mechanistic studies show it reduces M1 macrophage-driven chronic inflammation that causes insulin resistance.
Large prospective epidemiological studies associate high BCX intake with 15–40% reduced risk of lung cancer. BCX suppresses cigarette smoke-induced lung inflammation, oxidative DNA damage, and squamous metaplasia in animal models. Epidemiological evidence is supported by consistent inverse associations across multiple cohort studies.
Serum BCX levels are significantly lower in patients with exudative AMD compared to controls in case-control studies. Meta-analyses show consistent inverse associations between BCX and AMD risk. Animal data demonstrate BCX protects against light-induced retinal photoreceptor loss through antioxidant and anti-inflammatory mechanisms.
Epidemiological studies consistently show inverse associations between serum BCX and metabolic syndrome prevalence. BCX regulates NF-κB and Nrf2 pathways implicated in MetS, and reduces dyslipidemia, insulin resistance, and inflammatory markers in animal models. A C. elegans transcriptomic study supports metabolic syndrome pathway modulation.
A 2021 meta-analysis of 15 studies (100,496 individuals) found high BCX intake significantly reduced osteoporosis risk by 21% (OR=0.79). BCX stimulates osteoblastic bone formation and inhibits osteoclastic resorption via NF-κB suppression and TGF-β/SMAD activation. Epidemiological studies in postmenopausal women consistently support this association.
A population-based prospective study found BCX intake was 40% lower in incident inflammatory polyarthritis/RA cases. Higher BCX plasma levels are associated with lower RA risk in epidemiological studies of adults aged 45–75. Animal data show anti-arthritic effects on antigen-induced arthritis.
Body systems that Cryptoxanthin may help support.
Go back